The partners hope to identify pathogenic T cells that drive multiple sclerosis and the antigens that activate them.
CAMBRIDGE, Mass., March 31, 2021 /PRNewswire/ -- Flagship Pioneering today announced the expansion of its senior leadership team with the appointment of Michael T. Nally as CEO-Partner. In this role, Nally will bring his considerable expertise in biopharma to help achieve the highest possible value creation for Flagship and its companies. He will also serve as CEO of Generate Biomedicines, a company focused on pioneering a versatile Generative Biology platform to create a broad array of breakthrough therapeutics.
Diego Miralles, M.D., has joined Flagship Pioneering as CEO-partner. Flagship disclosed the appointment of Miralles, who will serve as CEO of its portfolio company Laronde, alongside news that it has hired ex-Rubius Therapeutics executive Andrew Oh as senior partner.
Earlier this month, Flagship announced their big bet on the software half the industry is talking about, launching the AI and machine learning startup. Now, they and a couple other investors are gambling $100 million on a software that much of the public generally thinks of as a cool, IT afterthought: cloud computing.
Flagship Pioneering has raised a $1.1 billion fund to create another batch of biotechs. The timing of the fund has Flagship peering into an uncertain future, trying to discern what opportunities will be attractive and impactful in the world that emerges from the COVID-19 pandemic.
Major venture capitalist firm Flagship Pioneering has brought together two of its sister biotech companies to create a new, singly focused effort.
More money is streaming into the coffers of Flagship Pioneering, one of the most prominent blank-slate venture funds in biotech. The VC group has closed $618 million in new funds, which is the biggest chunk of money it’s secured in almost two decades.